BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Phase 4

Completed

Conditions: Non-valvular Atrial Fibrillation

Interventions: Drug: Apixaban

First Posted Date: 2013-06-24

Last Posted Date: 2019-08-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1217

Registration Number: NCT01884350

Locations: 🇬🇧
Local Institution, Tauton, United Kingdom

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Phase 3

Terminated

Conditions: Chronic Hepatitis C Infection

Interventions: Biological: Pegylated Interferon Lambda-1a
Drug: Daclatasvir (DCV)
Drug: Ribasphere (RBV)

First Posted Date: 2013-06-03

Last Posted Date: 2023-06-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 453

Registration Number: NCT01866930

Locations: 🇬🇧
Local Institution, London, United Kingdom
🇨🇦
Mcgill University Health Centre (Muhc) Montreal Chest Institute, Montreal, Quebec, Canada
🇨🇦
St Pauls Hospital, Vancouver, British Columbia, Canada

and more 18 locations

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Metformin XR
Drug: Metformin IR
Drug: Placebo matching with Metformin XR
Drug: Placebo matching with Metformin IR

First Posted Date: 2013-05-29

Last Posted Date: 2019-11-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1736

Registration Number: NCT01864174

Locations: 🇵🇷
Policlinica Dr. Luis Rodriguez, Carolina, Puerto Rico
🇺🇸
Center For Clinical Trials Of Sacramento, Inc., Sacramento, California, United States
🇺🇸
Cedar-Crosse Research Ctr, Chicago, Illinois, United States

and more 44 locations

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Placebo
Drug: Abatacept

First Posted Date: 2013-05-23

Last Posted Date: 2022-04-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 489

Registration Number: NCT01860976

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Seattle Rheumatology Associates, Seattle, Washington, United States
🇺🇸
St. Paul Rheumatology, P.A., Eagan, Minnesota, United States

and more 30 locations

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ND-L02-s0201 Injection
Drug: Placebo

First Posted Date: 2013-05-21

Last Posted Date: 2017-05-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 56

Registration Number: NCT01858935

Locations: 🇺🇸
Quintiles Phase One Services, LLC, Overland Park, Kansas, United States

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

Phase 2

Completed

Conditions: Chronic Phase Chronic Myeloid Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2013-05-09

Last Posted Date: 2022-11-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT01850004

Locations: 🇮🇹
Local Institution - 0025, Catania, Italy
🇺🇸
Local Institution - 0013, Chicago, Illinois, United States
🇺🇸
Local Institution - 0006, Duarte, California, United States

and more 25 locations

Methotrexate-Inadequate Response Autoinjector Device Sub Study

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2013-05-03

Last Posted Date: 2015-07-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT01844895

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Phase 3

Completed

Conditions: Active Polyarticular Juvenile Idiopathic Arthritis

Interventions: Biological: Abatacept

First Posted Date: 2013-05-01

Last Posted Date: 2023-07-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 219

Registration Number: NCT01844518

Locations: 🇺🇸
Riley Hospital For Children, Indianapolis, Indiana, United States
🇺🇸
Seattle Children'S Hospital, Seattle, Washington, United States
🇧🇪
Local Institution - 0036, Gent, Belgium

and more 52 locations

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3

Completed

Conditions: Unresectable or Metastatic Melanoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Biological: Placebo for Nivolumab
Biological: Placebo for Ipilimumab

First Posted Date: 2013-05-01

Last Posted Date: 2024-07-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1296

Registration Number: NCT01844505

Locations: 🇺🇸
Maine Center For Cancer Medicine, Scarborough, Maine, United States
🇦🇺
Local Institution - 0017, Camperdown, New South Wales, Australia
🇦🇺
Local Institution - 0138, North Sydney, New South Wales, Australia

and more 147 locations

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Recruiting

Conditions: Multiple Myeloma

First Posted Date: 2013-04-24

Last Posted Date: 2024-12-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2555

Registration Number: NCT01838512

Locations: 🇺🇸
Local Institution - 0011, Indianapolis, Indiana, United States
🇺🇸
Local Institution - 0028, Sherman, Texas, United States
🇫🇷
Local Institution - 0106, Cannes Cedex, France

and more 115 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy